Trial Profile
A 12-Week, International, Multicenter, Double-Blind, Randomized, Placebo-Controlled Comparison of the Efficacy and Safety of Oral UT-15C Sustained Release Tablets in Subjects With Pulmonary Arterial Hypertension
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 05 Jan 2024
Price :
$35
*
At a glance
- Drugs Treprostinil (Primary)
- Indications Pulmonary arterial hypertension
- Focus Registrational; Therapeutic Use
- Acronyms FREEDOM-M
- Sponsors United Therapeutics Corporation
- 18 May 2016 Pooled analysis results from FREEDOM-M, FREEDOM-C, FREEDOM-C2 trials are presented at the 112th International Conference of the American Thoracic Society
- 29 Jul 2014 Results published in an United Therapeutics Corporation Media Release.
- 25 Jun 2014 New trial record